Formulation and Evaluation of Valsartan Oral Dispersible Tablets by Direct Compression Method

The objective of the present study is to develop a pharmaceutically stable, cost effective and quality improved robust formulation of Valsartan Immediate Release tablets. The aim of work is related to the formulation and evaluation of 10mg of dispersible tablet. Valsartan belongs to a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Total nine formulations were prepared by direct compression method in which the concentration of the superdisintegrants is varied to evaluate the effect on the disintegration time of valsartan mouth dissolving tablets. The superdisintegrants, involved in preparation are Sodium starch glycolate, Avicel PH 102, Low HPC. The prepared batches of tablets were evaluated for micromeritic parameters, weight variation, hardness, friability, wetting time, In vitro dispersion time, drug content and In vitro dissolution studies. In Formulations F1, F2, F3, releases 89.83%, 91.10%, 96.20%, respectively, Formulation F4, F5, and F6, which release 85.11%, 88.71% and 90.44% respectively and. Formulation F7, F8, F9, releases 78.26%, 82.26%, 85.31%, respectively, at end of 15 minutes. Amongst all the developed formulations, valsartan mouth dissolving tablets formulated by using sodium starch glycolate as superdisintegrants, having hardness (3.7 Kg/cm), Friability (0.1356 %), Drug Content (9.9250.067 mg). and it is fulfilling all the parameters. It has shown good In vitro disintegration time (8.00  1.023 sec), In vitro dispersion time (14.33  1.24 sec), compared to other superdisintegrants. The optimized formulation (F3) containing Sodium starch glycolate, as superdisintegrant is producing best results compared to other formulations.